Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT01904175 | Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant | completed | — | 48 | Duke UniversityOTHER | 1 | May 5, 2016 | clinicaltrials |
| NCT01542944 | TevaGastrim for Stem Cell Mobilization Sibling Donors | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00000591 | T-Cell Depletion in Unrelated Donor Marrow Transplantation | completed | Phase 3 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Apr 15, 2016 | clinicaltrials |
| NCT01075425 | Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 41 | Virginia Commonwealth UniversityOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT00000603 | Cord Blood Stem Cell Transplantation Study (COBLT) | completed | Phase 2 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Apr 14, 2016 | clinicaltrials |
| NCT01751867 | An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome | completed | Phase 3 | 135 | Xian-Janssen Pharmaceutical Ltd.INDUSTRY | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00293384 | Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant | completed | N/A | 40 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01019317 | Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 151 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01398462 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 69 | JW PharmaceuticalINDUSTRY | 2 | Mar 8, 2016 | clinicaltrials |
| NCT01461538 | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | completed | Phase 2 | 84 | Seagen Inc.INDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00398138 | Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma | completed | Phase 1 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 2, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01690507 | Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） | completed | Phase 1 / Phase 2 | 29 | Chinese PLA General HospitalOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00023530 | Blood and Marrow Transplant Clinical Research Network | completed | N/A | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Feb 18, 2016 | clinicaltrials |
| NCT00986804 | Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant(AML MDS) | completed | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT01488565 | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for Thrombocytopenia(Aza-E) | completed | Phase 2 | 25 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 15, 2016 | clinicaltrials |
| NCT00526292 | Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant | completed | Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00597519 | A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy | completed | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 12, 2016 | clinicaltrials |
| NCT00892190 | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | completed | Phase 1 | 9 | University of PittsburghOTHER | 1 | Feb 10, 2016 | clinicaltrials |
| NCT00648037 | Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCT | completed | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 1, 2016 | clinicaltrials |
| NCT01338337 | Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia(ABRAZA) | completed | Phase 2 | 40 | Asociación Andaluza de Hematología y HemoterapiaOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00014495 | Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer | completed | Phase 1 / Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 22, 2016 | clinicaltrials |
| NCT01822691 | Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 18, 2016 | clinicaltrials |
| NCT01336712 | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases | completed | Phase 2 | 30 | Northside Hospital, Inc.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00731328 | Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome | completed | Phase 2 | 15 | Asan Medical CenterOTHER | 1 | Dec 31, 2015 | clinicaltrials |
| NCT02007863 | Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia | completed | N/A | 2 | University of MiamiOTHER | 1 | Dec 28, 2015 | clinicaltrials |
| NCT00002718 | T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia | completed | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00028730 | Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT00606216 | Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With Radiotherapy | completed | — | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2015 | clinicaltrials |
| NCT00459212 | GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00491634 | Treosulfan-based Conditioning for Transplantation in AML/MDS | completed | Phase 2 | 24 | Dr. Avichai Shimoni MDOTHER_GOV | 1 | Dec 2, 2015 | clinicaltrials |
| NCT01135849 | B-Receptor Signaling in Cardiomyopathy | completed | — | 99 | Daniel BernsteinOTHER | 1 | Nov 17, 2015 | clinicaltrials |
| NCT01192945 | Non-interventional Study With Azacitidin (Vidaza®)(Piaza) | completed | — | 150 | iOMEDICO AGINDUSTRY | 1 | Nov 13, 2015 | clinicaltrials |
| NCT00299156 | Oral Clofarabine Study in Patients With Myelodysplastic Syndrome | completed | Phase 2 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2015 | clinicaltrials |
| NCT00134004 | Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT02188290 | Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation | completed | — | 178 | Kiadis PharmaINDUSTRY | 6 | Oct 6, 2015 | clinicaltrials |
| NCT00479232 | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | completed | Phase 1 | 71 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2015 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT00086125 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | completed | Phase 2 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT01362985 | Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor | completed | — | 201 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Aug 13, 2015 | clinicaltrials |
| NCT00588809 | Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Aug 5, 2015 | clinicaltrials |
| NCT00274781 | Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 2 | 30 | The Cleveland ClinicOTHER | 1 | Jul 10, 2015 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00324220 | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 66 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jul 1, 2015 | clinicaltrials |
| NCT00954941 | Ondansetron Versus Aprepitant Plus Ondansetron for Emesis | completed | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2015 | clinicaltrials |
| NCT00990587 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | completed | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT00034684 | Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701) | completed | Phase 1 / Phase 2 | 132 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2015 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2016source: clinicaltrials